RELAPSED/REFRACTORY LIGHT CHAIN AMYLOIDOSIS

Clinical trials for RELAPSED/REFRACTORY LIGHT CHAIN AMYLOIDOSIS explained in plain language.

Never miss a new study

Get alerted when new RELAPSED/REFRACTORY LIGHT CHAIN AMYLOIDOSIS trials appear

Sign up with your email to follow new studies for RELAPSED/REFRACTORY LIGHT CHAIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Engineered immune cells take aim at rare amyloid disease

Disease control Recruiting now

This early-phase study tests a personalized cell therapy (CAR-T cells) in 30 adults with relapsed or hard-to-treat light chain amyloidosis, a rare disease where abnormal proteins damage organs. The treatment targets BCMA on harmful plasma cells to reduce protein buildup. The main…

Matched conditions: RELAPSED/REFRACTORY LIGHT CHAIN AMYLOIDOSIS

Phase: EARLY_PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control

Last updated Jun 15, 2026 19:05 UTC

RELAPSED/REFRACTORY LIGHT CHAIN AMYLOIDOSIS

Get alerted when new RELAPSED/REFRACTORY LIGHT CHAIN AMYLOIDOSIS trials appear

Engineered immune cells take aim at rare amyloid disease